^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vudalimab (XmAb717)

    i
    Other names: XmAb717, XmAb 20717, XmAb20717, XmAb 717, XmAb-717, XmAb-20717
    Company:
    Xencor
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    12d
    XmAb717-06: Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC (clinicaltrials.gov)
    P1/2, N=28, Terminated, Xencor, Inc. | N=168 --> 28 | Trial completion date: Oct 2027 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Dec 2025; Business Decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement • ROS1 rearrangement
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • vudalimab (XmAb717)
    5ms
    Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer (clinicaltrials.gov)
    P2, N=54, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jul 2027 | Trial primary completion date: Jul 2024 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • CD4 (CD4 Molecule)
    |
    BRAF V600E
    |
    vudalimab (XmAb717)
    6ms
    Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov)
    P1, N=4, Terminated, Emory University | N=30 --> 4 | Trial completion date: Dec 2027 --> Jun 2025 | Suspended --> Terminated | Trial primary completion date: Dec 2026 --> Jun 2025; To review the safety data.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • vudalimab (XmAb717)
    8ms
    XmAb20717-04: XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=72, Completed, Xencor, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    TMB-H • MSI-H/dMMR
    |
    Lynparza (olaparib) • carboplatin • docetaxel • cabazitaxel • vudalimab (XmAb717)
    11ms
    XmAb20717-04: XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=72, Active, not recruiting, Xencor, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Jun 2025
    Enrollment closed • Trial completion date • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    TMB-H • MSI-H/dMMR
    |
    Lynparza (olaparib) • carboplatin • docetaxel • cabazitaxel • vudalimab (XmAb717)
    11ms
    A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers (clinicaltrials.gov)
    P2, N=140, Suspended, M.D. Anderson Cancer Center | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    vudalimab (XmAb717)
    1year
    XmAb20717-05: A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies (clinicaltrials.gov)
    P2, N=170, Active, not recruiting, Xencor, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    vudalimab (XmAb717)
    over1year
    XmAb20717 in Advanced Biliary Tract Cancers (clinicaltrials.gov)
    P2, N=27, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    IDH1 mutation • FGFR2 mutation • FGFR2 fusion • IDH mutation + NTRK fusion • NTRK fusion
    |
    vudalimab (XmAb717)
    over1year
    Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov)
    P1, N=30, Suspended, Emory University | Recruiting --> Suspended
    Trial suspension
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • vudalimab (XmAb717)
    over1year
    XmAb20717-05: A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies (clinicaltrials.gov)
    P2, N=170, Recruiting, Xencor, Inc. | Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Oct 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    vudalimab (XmAb717)
    almost2years
    A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers (clinicaltrials.gov)
    P2, N=140, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended
    Trial suspension • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    vudalimab (XmAb717)
    almost2years
    XmAb20717 in Advanced Biliary Tract Cancers (clinicaltrials.gov)
    P2, N=27, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial primary completion date • Metastases
    |
    FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion
    |
    vudalimab (XmAb717)